Drug General Information
Drug ID
D0V1SB
Former ID
DAP001488
Drug Name
Lanreotide Autogel
Drug Type
Small molecular drug
Indication Acromegaly [ICD9: 253; ICD10:E22.0] Approved [536151]
Company
Ipsen
Structure
Download
2D MOL

3D MOL

Formula
C54H69N11O10S2
Canonical SMILES
CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CC<br />CCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=<br />CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N
InChI
1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
InChIKey
PUDHBTGHUJUUFI-UHFFFAOYSA-N
CAS Number
CAS 108736-35-2
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
H01CB03
SuperDrug CAS ID
cas=108736352
Target and Pathway
Target(s) Somatostatin receptor type 2 Target Info Binder [536151]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gastric acid secretion
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways SIDS Susceptibility Pathways
GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 536151Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
Ref 536151Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.